The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib

Author:

O’Sullivan Jennifer M.123,Hamblin Angela45,Yap Christina67,Fox Sonia6,Boucher Rebecca6ORCID,Panchal Anesh6,Alimam Samah1,Dreau Helene4,Howard Kieran4,Ware Pauline4,Cross Nicholas C. P.8,McMullin Mary Frances9ORCID,Harrison Claire N.1,Mead Adam J.235ORCID

Affiliation:

1. Department of Haematology, Guy’s and St. Thomas’ National Health Service (NHS) Foundation Trust, London, United Kingdom;

2. Haematopoietic Stem Cell Biology Laboratory and

3. Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom;

4. Oxford Molecular Diagnostics Centre, Oxford, United Kingdom;

5. National Institute for Health Research (NIHR) Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom;

6. Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom;

7. The Institute of Cancer Research, London, United Kingdom;

8. Wessex Regional Genetics Laboratory, Salisbury, United Kingdom; and

9. Department of Haematology, Queen’s University, Belfast, United Kingdom

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3